Compound reference
Ipamorelin, CJC-1295 No DAC (Blend)
Growth Hormone Research · vial. For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.
Chemistry identity
Reference identifiers
COA documentation
Lot record status
COA on file - lab confirmation pendingView Lab ReportsPublished literature
Research context
Peer-reviewed literature referencing this compound, provided for research context.
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism2024
Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, et al.
Physiology & behavior
In a ferret model of cisplatin-induced gastrointestinal disruption, this ghrelin receptor (GHS-R1a) agonist reduced electrically-stimulated contractions of isolated ileal tissue by approximately 54%, and attenuated chemotherapy-associated declines in body mass during the delayed phase of the model, supporting a peripheral ghrelin-receptor mechanism in gut motility and appetite-regulation research.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults2006
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
The Journal of clinical endocrinology and metabolism
This is the foundational receptor-pharmacology and pharmacokinetic-profiling study of a DAC-conjugated, long-acting analog built on the same GHRH(1-29) backbone as CJC-1295 -- a distinct, extended-half-life variant, NOT the unconjugated No-DAC form sold under this listing. The study established sustained, concentration-dependent, GHRH-receptor-mediated increases in growth hormone and IGF-I signaling for that conjugated analog, with an estimated elimination half-life of 5.8-8.1 days specific to the DAC-bound form; this half-life figure does not apply to the short-acting No-DAC peptide in this product.
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro2002
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G
Histology and histopathology
In cultured rat anterior pituitary cells following 21 days of in vivo administration, this GH secretagogue increased somatotroph secretory granule density and modulated intracellular GH content in a manner comparable to GHRH, indicating a receptor-mediated action on somatotroph cell physiology in this rodent model.
Do growth hormone-releasing peptides act as ghrelin secretagogues?2001
Ahnfelt-Rønne I, Nowak J, Olsen UB
Endocrine
In rats, whole-body autoradiography showed this class of GH-releasing peptides (an ipamorelin-derived analog, NN703) accumulates in the glandular stomach, the site of ghrelin synthesis, and surgical removal of the gastrointestinal tract attenuated GH release by 60-70%, indicating ghrelin-receptor-mediated signaling contributes to the peptide class's mechanism of action.
Catalog access requires an account and acceptance of a research-use disclaimer.
This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such.